Mirum Pharmaceuticals Inc

NASDAQ:MIRM   3:59:52 PM EDT
24.46
+0.05 (+0.20%)
Earnings Announcements

Mirum Pharmaceuticals Q2 Loss Per Share $0.84

Published: 08/04/2022 20:42 GMT
Mirum Pharmaceuticals Inc (MIRM) - Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update.
Net Product Sales for Livmarli(® )(maralixibat) Oral Solution Totaled $17.5 Million in Q2 of 2022.
Q2 Loss per Share $0.84.
Revenue is expected to be $20.32 Million
Adjusted EPS is expected to be -$1.05

Next Quarter Revenue Guidance is expected to be $21 Million
Next Quarter EPS Guidance is expected to be -$0.93

More details on our Analysts Page.